AdVia- Kidney Study 1

  • Research type

    Research Study

  • Full title

    AdVia- Kidney Study 1- identification and prioritisation of viral candidates for further development for use as gene therapy for Kidney Disease

  • IRAS ID

    354496

  • Contact name

    William Taverner

  • Contact email

    w.taverner@adviatx.com

  • Sponsor organisation

    AdVia Therapeutics UK Ltd

  • Duration of Study in the UK

    5 years, 0 months, 15 days

  • Research summary

    Many genetic disorders effect the kidney, including but not limited to Polycystic kidney disease and Aloport's syndrome causing suffering to those afflicted. New treatments are desperately needed to improve the quality of life for these patients. In order to understand the disease in more detail and to test new therapeutic ideas, it is necessary to study diseased cells in the laboratory. While some artificial cell lines are available for basic research there is no real substitute to human cells isolated directly from tissue. IThis study requires kidney tissue from healthy or diseased kidneys that are deemed unsuitable for transplant. This study can use partial kidneys or areas of kidneys that have not been impacted by a disease state (for example we could use a healthy section of a metastatic kidney). Only samples with consent for commercial research purposes will be used.

  • REC name

    South West - Frenchay Research Ethics Committee

  • REC reference

    25/SW/0051

  • Date of REC Opinion

    24 Apr 2025

  • REC opinion

    Favourable Opinion